ReviewSaudi journal of biological sciences2021
Wonder or evil?: Multifaceted health hazards and health benefits of
Review in Saudi journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Cannabinoids: Therapeutic Perspectives for Management of Orofacial Pain, Oral Inflammation and Bone Healing-A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Phytotherapy for Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review and Meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Cannabidiol in Food and Food Supplements: Drug, Novel Food and Hazard Triangle.Molecules (Basel, Switzerland) · 2026Article
- Reasons for Using Cannabis Among Adults in the United States: Associations with Demographics, Health Behaviors, Chronic Conditions, and Legal Status.International journal of environmental research and public health · 2026Article
- Phytocannabinoids and Male Fertility: Implications ofPlants (Basel, Switzerland) · 2026Review
- The addictive and neurotoxicological evaluation ofIBRO neuroscience reports · 2025Article
- A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Plant-derived polyphenolic compounds for managing schizophrenia: mechanisms and therapeutic potential.Frontiers in pharmacology · 2025Review
- Article
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes & diseases · 2023Review
- [Optimized chromatographic methods for the identification and quantification of terpenes in Cannabis sativa oil for medicinal use]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2023Article
- Cognitive Health in Persons With Human Immunodeficiency Virus: The Impact of Early Treatment, Comorbidities, and Aging.The Journal of infectious diseases · 2023Article
- Drug Development Strategies for Malaria: With the Hope for New Antimalarial Drug Discovery-An Update.Advances in medicine · 2023Review
- Pharmacological screening of silibinin for antischizophrenic activity along with its acute toxicity evaluation in experimental animals.Frontiers in pharmacology · 2023Article
- Article
- Betelvine (Piper betle L.): A comprehensive insight into its ethnopharmacology, phytochemistry, and pharmacological, biomedical and therapeutic attributes.Journal of cellular and molecular medicine · 2022Review
- Hemp and Its Derivatives as a Universal Industrial Raw Material (with Particular Emphasis on the Polymer Industry)-A Review.Materials (Basel, Switzerland) · 2022Review
- Biotechnology for propagation and secondary metabolite production in Bacopa monnieri.Applied microbiology and biotechnology · 2022Review
- Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia.Frontiers in pharmacology · 2022Review
- Unravelling the Therapeutic Potential of Botanicals Against Chronic Obstructive Pulmonary Disease (COPD): Molecular Insights and Future Perspectives.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.